The Global Fund is an international financing mechanism charged with mobilization and disbursement of additional resources to countries to address high disease burden among populations afflicted by HIV/AIDS, Tuberculosis and Malaria. Kenya is running the 7th largest Global Fund portfolio globally. This puts the country in a critical position to demonstrate results in bringing more patients to treatment, alleviating suffering, ensuring accountability, engaging in meaningful partnerships and strengthening the health and community systems.
On Friday the 15th December, 2017 Kenya enters into an agreement with the Global Fund to fight HIV and AIDS, Tuberculosis (TB) and Malaria (GFATM) for a funding support of USD 380Million (KShs. 38 billion) for the period January 2018 to June 2021. This is a culmination of a partnership with Global Fund, which has supported Kenya since 2002. As part of our sustainability strategy, the Government of Kenya has continued to meet its obligation of Co-financing requirements of 20% . The Government has allocated Ksh 10.2 Billion for the period 2018 to 2021 to support HIV, Tuberculosis and Malaria interventions in Kenya.
Global Fund Tuberculosis Grants
Kenya signed Tuberculosis grants amounting to KShs 6.3 billion for January 2018 – June 2021. The funds will be managed by two Principal Recipients:
- The National Treasury, KShs 3.0 billion
- Amref Health Africa, KShs 3.3 billion
The funds will support:
- Procurement of TB Medicines ,equipment ,diagnostic supplies and therapeutic feeds
- Complement Government efforts by putting about 338,550 new TB cases on treatment by 2021.
- Provision of medicine to 1,890 drug resistance Tuberculosis Cases until June 2021.
- Short term regimen for treatment of Drug resistant TB cases, which has shorten treatment from 24 months to 9 months.
- Capacity Building of Facility and Community Health workers